Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is facing a variety of risks, including clinical and regulatory, financial, commercial, legal and intellectual property, and market share risks. However, the company expects an improvement in revenue growth through 2026 and a return to growth in both the US and international markets. The recently implemented leadership transition and focus on sales force productivity, account quality, and cost control may help stabilize the company, and upcoming earnings will provide insight into whether U.S. treatment center utilization and patient conversion can reaccelerate.

Bears say

Pulmonx is facing several challenges, including weaker U.S. performance and slower procedure growth, as the company struggles to maintain operational discipline and reaccelerate commercial efforts. The company's financial results for the fourth quarter and full year of 2025 showed modest annual growth but a decline in quarterly revenue, indicating a transitional period for the company. In order to regain investor confidence, Pulmonx will need to demonstrate a clean fourth quarter print and show improvement in procedural velocity and cost control while remaining the leader in bronchoscopic lung volume reduction.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.